Cable Car Capital LP Invests $696,000 in Curis, Inc. $CRIS

Cable Car Capital LP purchased a new position in shares of Curis, Inc. (NASDAQ:CRIS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,333,334 shares of the biotechnology company’s stock, valued at approximately $696,000. Cable Car Capital LP owned approximately 63.80% of Curis as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Armistice Capital LLC increased its position in Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 78,265 shares during the period. Maverick Capital Ltd. lifted its holdings in shares of Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after buying an additional 49,554 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after buying an additional 65,404 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 230,659 shares in the last quarter. Finally, Squarepoint Ops LLC grew its holdings in Curis by 17.9% during the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 8,973 shares during the period. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Stock Performance

Shares of CRIS stock opened at $1.59 on Wednesday. The stock has a fifty day moving average price of $4.87 and a 200 day moving average price of $10.88. The stock has a market cap of $3.32 million, a PE ratio of -0.11 and a beta of 3.13. Curis, Inc. has a 1 year low of $1.50 and a 1 year high of $39.00.

Curis (NASDAQ:CRIS) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. As a group, equities research analysts predict that Curis, Inc. will post -24.23 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on CRIS. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Curis in a report on Monday, August 17th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $43.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.